Clinical Trials Epilepsy Safety Therapy 
MMJ Recs
NOVEMBER 30, 2023
Epilepsy is a complex neurological disorder that affects millions of people worldwide, causing recurrent seizures that can significantly impact the quality of life. Medical Marijuana for Epilepsy Treatment Medical marijuana, often referred to as MMJ, is a term used to describe the use of cannabis and its derivatives for therapeutic purposes.
MMJ Recs
APRIL 1, 2024
Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MMJ Recs
NOVEMBER 20, 2023
Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Researchers have been conducting clinical studies to investigate the safety and efficacy of cannabinoid-based treatments. Image by Pfüderi from Pixabay.
MMJ Recs
DECEMBER 28, 2023
However, more research is needed to establish standardized treatment protocols and ensure the long-term safety and efficacy of medical marijuana in managing PTSD. CBD has emerged as a potential anticonvulsant, with several studies suggesting its effectiveness in reducing seizure frequency in certain types of epilepsy.
Veriheal
APRIL 11, 2022
I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We
Cannabis Law Report
AUGUST 21, 2019
The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. This would answer questions about safety and efficacy, they said.
Cannabis Law Report
NOVEMBER 16, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. Chapman continued.
Expert insights. Personalized for you.
105 
Let's personalize your content